Eagle Pharmaceuticals granted unique J-code for Byfavo from the CMS

Eagle Pharmaceuticals announced that the Centers for Medicare & Medicaid Services – CMS – has established a unique, product-specific billing code for Byfavo – remimazolam for injection -, a short-acting sedative for procedures lasting 30 minutes or less. This new Healthcare Common Procedure Coding System Level II code, or J-code, will be effective on July 1. J-codes are reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for physician-administered drugs like Byfavo and are intended to simplify the claims submission and documentation process, facilitating access for patients.